CEO John Tchelingerian to Discuss Strategic Collaborations and Partnering Strategies in Cell Therapy at ARM’s Advanced Therapies Summit
Mont-Saint-Guibert, Belgium, March 15, 2017 – Promethera Biosciences SA, a global innovator in cell-based medicines, will participate in the following industry conferences in March:
Date: March 20, 2017
Venue: Barcelona, Spain
Participants: John Tchelingerian, Chief Executive Officer, and Henrik Luessen, Chief Business Officer
7th Annual Advanced Therapies Summit
Date: March 22, 2017
Venue: Barcelona, Spain
Participants: John Tchelingerian, Chief Executive Officer
The Advanced Therapies Summit is a multi-stakeholder, interactive forum that seeks to exchange views and make recommendations on how best to advance the advanced therapy medicinal products sector in Europe. The conference brings together the top executives, clinical researchers, public policy makers and other members of the advanced therapies community to highlight the major achievements as well as the main challenges experienced along the path from discovery to delivery of transformative – and even potentially curative – therapies.
About Promethera Biosciences
Promethera Biosciences is a global innovator in liver cell-based medicines whose mission is to help patients overcome acute and chronic liver diseases. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. We are a team of international experts operating out of R&D and GMP facilities in Mont-Saint-Guibert, Belgium, and Durham, NC, USA.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community.
Today, ARM has more than 250 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.